Getting German health insurance claims data wrong at the start cascades through every downstream deliverable in your HEOR strategy. One decision determines whether you can actually access the data you need: does your research purpose qualify as public interest, or is it commercial?
Key Takeaways
- German statutory health insurance (SHI) claims data offer longitudinal, population-scale evidence stretching back to 2009 – a powerful foundation for HEOR and market access studies.
- FDZ Gesundheit covers roughly 90% of the German population but restricts access to public-interest research, making it unsuitable for commercially oriented market access work.
- Commercial providers such as InGef, INSIGHT Health, and IQVIA Germany offer faster access and iterative flexibility – critical when working against reimbursement deadlines.
- The right access route is determined first by research purpose; everything else – timeline, population size, regulatory credibility – follows from that.
- Upcoming changes under the GDNG and the European Health Data Space (EHDS) are actively reshaping what is possible with German health data, covered further below.
One Decision Shapes Your Entire HEOR Strategy
Choosing between statutory and commercial access to German claims data is not simply a procurement decision. The choice dictates study feasibility, timeline, regulatory defensibility, and the scope of evidence that can actually be generated. Getting it wrong early sends consequences rippling through every downstream deliverable – from the study protocol to the payer submission.
The German health data landscape has become considerably more structured since the Gesundheitsdatennutzungsgesetz (GDNG) came into force in March 2024. More structure, however, also means more rules to navigate. MEDDDICAL’s guide to German health data providers and claims data under the GDNG maps the full landscape for HEOR and market access teams trying to orient themselves in this space.
The core question is straightforward: does the research purpose open the statutory door, or does operational reality point toward a commercial route? Everything else flows from that.
What German Claims Data Actually Covers
German SHI claims data are generated through routine reimbursement processes – not clinical studies. That distinction matters. The data reflect real prescribing behaviour, hospital admissions, diagnostic coding, and cost patterns across the actual insured population, free from the selection effects that shape clinical trials.
Longitudinal Depth Since 2009
FDZ Gesundheit data runs continuously from 2009, with increasing clinical granularity through Data Model 3 from 2019 onwards. That longitudinal depth enables disease burden analyses, long-term treatment pathway mapping, and outcomes tracking that short-term data cannot support. For rare diseases in particular – where the Haemophilia A literature has shown that claims data can reliably capture patient characteristics, treatment sequencing, resource use, and costs – this time span is often decisive.
Where the Clinical Gaps Lie
Claims data are strong on utilisation; they are weaker on clinical nuance. Laboratory values, self-paid services, lifestyle risk factors, and clinical staging are largely absent. These gaps are real and should be planned for. Linking SHI claims with electronic medical records (EMR) or disease registries is the standard mitigation, though it adds design complexity. Knowing the limitation before study design begins – not after – is what separates efficient evidence generation from expensive rework.
FDZ Gesundheit: The Case for Statutory Access
The FDZ Gesundheit is the centralised research data centre established under the GDNG to provide pseudonymised SHI claims data from all statutory health insurers through a single, consolidated access point. Before its creation, researchers had to negotiate bilateral arrangements with individual funds – producing datasets that were often geographically and demographically unrepresentative. That fragmentation is now largely resolved.
90% Population Coverage
Approximately 90% of the German population is covered by statutory health insurance, and FDZ Gesundheit data reflects that breadth. For studies requiring national representativeness – population-level epidemiology, burden-of-disease analyses, or research feeding into regulatory submissions – no commercial dataset can match that coverage. It is a genuine structural advantage for the right type of study.
Who Can Actually Apply
Access is open to eligible organisations within the EU or EEA, but the permitted purposes are tightly defined. The GDNG restricts FDZ access to public-interest research. Projects centred on market research, product commercialisation, or competitive intelligence fall explicitly outside these permitted purposes. This is not a procedural technicality – it is the primary filter that determines whether the statutory route is viable at all.
The Application Timeline Reality
Application review timelines are currently measured in months. For teams working toward a fixed AMNOG submission window or a launch-readiness milestone, this is a meaningful constraint. FDZ is also developing a Public Use File (PUF) for Data Models 1, 2, and 3 – a fully anonymised dataset with the same structure as the live data, allowing teams to develop and test analysis scripts ahead of formal approval. This can shorten the overall project duration once access is granted, but it does not eliminate the front-end wait.
Commercial Providers: Speed and Flexibility
Commercial providers – including InGef, INSIGHT Health, and IQVIA Germany – access German SHI data through licensing arrangements. Datasets are derived from voluntarily contributed claims data and anonymised to GDPR standards. They are smaller than the FDZ universe, but purpose-built for the operational realities of pharmaceutical evidence generation.
Iterative Research Without Bottlenecks
The practical advantage is flexibility. Commercial providers typically offer special data-analyst teams, faster project initiation, and the ability to refine inclusion criteria, run sensitivity analyses, and update studies without restarting a formal application cycle. For organisations managing multiple evidence deliverables across a product lifecycle – early market assessment, payer negotiation support, post-launch outcomes tracking – this iterative capacity is often the deciding factor.
InGef’s database currently includes approximately 10.5 million insured persons, with around 7.8 million actively insured in 2025, and carries strong regulatory credibility as an official data partner in the European DARWIN EU network – which matters when study outputs are intended for regulatory or HTA audiences. The commercial route does not automatically mean lower scientific rigour; it means different governance, faster timelines, and greater design freedom.
Purpose Eligibility Is the First Filter
Before assessing coverage, timeline, or cost, the research purpose must be evaluated against the statutory access criteria. If the primary objective is commercial – generating evidence to support a pricing negotiation, a market access dossier, or a competitive positioning exercise – FDZ Gesundheit is not an eligible route. Attempting to frame a commercially motivated study as public-interest research to gain statutory access is not a workaround; it is a compliance risk.
Conversely, if the study genuinely qualifies as public-interest research – independent epidemiology, health services research, or academic collaboration – defaulting to a commercial provider purely for speed may sacrifice the population coverage and regulatory credibility that the FDZ route provides. Purpose eligibility is both a legal and a strategic question.
Decision Framework: Five Questions to Ask First
Before committing to either route, these five questions should be answered explicitly – ideally before the study protocol is drafted:
- What is the primary purpose of the study? Public-interest research or commercially oriented evidence generation?
- Does the project qualify for statutory access? Assess honestly against GDNG-defined permitted purposes.
- Is national population representativeness required? If yes, FDZ coverage becomes a hard requirement, not a preference.
- What is the realistic timeline? Factor in the months-long application process for FDZ; assess whether the PUF option changes the calculus.
- Will the analysis require iteration? Multiple sensitivity analyses, subgroup explorations, or future publication updates favour a commercial setup.
These questions do not make the decision automatically, but they surface the trade-offs early enough to act on them.
GDNG and EHDS Are Redrawing the Landscape
The GDNG, enacted in March 2024, is the most significant structural reform to German health data access in years. By consolidating SHI data from all statutory insurers into a single regulated access point, it addressed the fragmentation that had long undermined the representativeness of German research datasets. The FDZ Gesundheit is the operational expression of that reform.
Because FDZ access is limited to legally defined research purposes, organisations should assess eligibility before building a study around this route. See How to Access German Claims Data under the GDNG.
Layered on top of this is the European Health Data Space (EHDS) – the EU-level framework designed to enable cross-border secondary use of health data for research, policy, and innovation. For HEOR and market access teams planning multi-country evidence strategies, EHDS will eventually change what pan-European real-world evidence looks like. Germany, as one of Europe’s largest health systems, sits at the centre of that shift.
Neither development simplifies the immediate decision between statutory and commercial access. Both do signal, however, that the governance infrastructure around German health data is maturing rapidly – and that teams building long-term evidence generation capabilities need to track these changes actively, not reactively.
Fit Determines Value – Choose Accordingly
There is no universally superior access route. FDZ Gesundheit delivers unmatched population coverage and regulatory credibility for studies that qualify, and the GDNG has made that pathway more coherent than it has ever been. Commercial providers deliver speed, flexibility, and iterative capacity for the commercially oriented evidence programmes that make up a significant share of pharmaceutical HEOR work.
Treating the choice as a default rather than a deliberate decision is where teams go wrong. Selecting a data source before clarifying research purpose, timeline constraints, and downstream use of evidence is how projects end up mid-course, with a chosen route that cannot deliver what the study actually requires.
Fit – between study objective, access route, and operational reality – is what determines whether a German claims data study generates genuine value or simply generates output.
For HEOR and market access programmes, the decision often comes down to more than data coverage. Choosing between statutory and commercial data sources can help organisations assess the trade-offs between coverage, eligibility, flexibility and project timelines.
For HEOR and market access teams working through these decisions, MEDDDICAL provides expert guidance on German health data access, study design, and evidence strategy across both statutory and commercial routes.